New hope for seniors with hard-to-treat lymphoma: drug combo targets double/triple-hit cancers
NCT ID NCT07552324
First seen Apr 28, 2026 · Last updated May 07, 2026 · Updated 3 times
Summary
This study tests a new combination of drugs for people aged 65 and older with a fast-growing type of lymphoma called double/triple-hit diffuse large B-cell lymphoma, who cannot have a stem cell transplant. The treatment includes several chemotherapy drugs plus two newer targeted agents. The goal is to see how many patients achieve complete remission and how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.